About ZRC

Zydus’ Innovation programme is spearheaded by 1200 researchers across 19 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas and concepts to bring in a relentless flow of innovation.
In 2013, the group was the first to identify and develop Lipaglyn™ (Saroglitazar) and launch India’s first NCE in the market. Recently at the end of 2014, the group launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis.

The major areas of research includes :